top of page

GPCR News 

Post: Blog2_Post

Exscientia is 10 years old this July!

July 2022


"Today we are celebrating ten years of Exscientia! Founded as a spinout from the University of Dundee on 20 July 2012, Exscientia pioneered the design of novel compounds through artificial intelligence. We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates to enter clinical trials, the first AI-driven precision medicine platform clinically validated to guide treatment selection in patients with advanced haematological cancers, international partnerships with pharma and healthcare foundations, and the establishment of a global company with locations in the UK, U.S., Austria, and Japan which IPO’d in October last year. We’re excited about delivering the next ten years of Exscientia and advancing AI to design better drugs, faster.


2 views0 comments

Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin

Comments